2025-05-28 - Analysis Report
Okay, here's an analysis of Transmedics Group Inc (TMDX) based on the provided data. The report is structured with numbers first, followed by a brief analysis.

**Transmedics Group Inc (TMDX) Analysis**

Transmedics Group Inc is a medical technology company focused on developing and delivering innovative organ preservation systems for transplantation therapy.

**1. Performance vs. S&P 500 (VOO)**

*   **TMDX Cumulative Return:** 250.9%
*   **VOO Cumulative Return:** 54.5%
*   **Absolute Divergence (Current):** 196.4%
*   **Relative Divergence:** 73.6% (meaning it's in the upper range of historical divergence).

**Analysis:** TMDX has significantly outperformed the S&P 500. The relative divergence indicates that the current outperformance is substantial compared to its historical range.

**Alpha, Beta Analysis Table**

| Year       | CAGR    | MDD    | Alpha   | Beta  | Cap(B) |
|------------|---------|--------|---------|-------|--------|
| 2019-2021  | -4.0%   | 63.4%  | -57.0%  | 0.0   | 0.7    |
| 2020-2022  | 140.0%  | 68.3%  | 134.0%  | 0.0   | 2.1    |
| 2021-2023  | 95.0%   | 69.4%  | 79.0%   | 0.3   | 2.7    |
| 2022-2024  | 147.0%  | 82.8%  | 130.0%  | 0.3   | 2.1    |
| 2023-2025  | 132.0%  | 82.8%  | 101.0%  | 0.5   | 4.3    |

**Analysis:**

*   **CAGR:**  Shows very strong growth in recent periods.
*   **MDD:**  Maximum Drawdown figures are quite high, indicating significant volatility and risk.
*   **Alpha:** Consistently high positive alpha indicates significant outperformance relative to the market risk-free rate.
*   **Beta:** Beta values suggest TMDX's price is more volatile than the S&P 500

**2. Recent Price Action**

*   **Current Price:** \$128.53
*   **Previous Close:** \$124.25
*   **Change:** \$3.44 (Significant jump)
*   **5-day Moving Average:** \$124.43
*   **20-day Moving Average:** \$110.09
*   **60-day Moving Average:** \$86.40

**Analysis:** The stock is trading well above its moving averages, indicating strong upward momentum. The significant price increase from the previous close suggests a potential breakout or reaction to recent news.

**3. Technical Indicators and Expected Return**

*   **MRI (Market Risk Indicator):** 0.366 (Low Risk)
*   **RSI:** 86.07 (Overbought)
*   **PPO:** 0.0036
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.37)
*   **20-day Relative Divergence Change:** +5.2 (Short-term Increase)
*   **Expected Return:** 37.3% (Long-term, relative to S&P 500)

**Analysis:**

*   The RSI indicates the stock is overbought and may be due for a correction.
*   The Hybrid Signal is cautioning.
*   The MRI suggests a low-risk environment, but this should be balanced with the overbought RSI.
*   The positive change in relative divergence confirms recent outperformance.
*   A high Expected Return suggests that, from today's level, TMDX is likely to outperform the S&P 500 considerably over the long term.

**4. Recent News & Significant Events**

*   **May 28, 2025:** Major business developments, regulatory changes, or market events.
*   **May 27, 2025:** Analyst discussion on recent performance and outlook.
*   **May 26, 2025:** Notable stock volatility influenced by news, earnings, or executive actions.
*   **May 24, 2025:** Market experts highlight risks and opportunities.

**Analysis:**  Recent news indicates significant activity and potential volatility in TMDX. Investors should monitor specific news sources for details on the developments.

**5. Recent Earnings Analysis**

| Date       | EPS   | Expected EPS |
|------------|-------|--------------|
| 2025-05-08 | 0.70  | 0.29         |
| 2025-02-27 | 0.19  | 0.22         |
| 2024-10-28 | 0.12  | 0.29         |
| 2024-07-31 | 0.35  | 0.21         |
| 2024-04-30 | 0.35  | 0.03         |

**Analysis:** TMDX has significantly exceeded EPS expectations in the most recent quarter (2025-05-08). This is likely contributing to the positive price action. Prior to that, results were mixed with some misses on expectations.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-03-31 | \$0.14B | 61.47%        |
| 2024-12-31 | \$0.12B | 59.21%        |
| 2024-09-30 | \$0.11B | 55.94%        |
| 2024-06-30 | \$0.11B | 60.59%        |
| 2024-03-31 | \$0.10B | 61.91%        |

**Capital and Profitability:**

| Quarter    | Equity   | ROE    |
|------------|----------|--------|
| 2025-03-31 | \$0.27B  | 9.64%  |
| 2024-12-31 | \$0.23B  | 3.00%  |
| 2024-09-30 | \$0.21B  | 2.01%  |
| 2024-06-30 | \$0.19B  | 6.42%  |
| 2024-03-31 | \$0.16B  | 7.65%  |

**Analysis:**

*   **Revenue:** Revenue is growing steadily.
*   **Profit Margin:** Profit margins are exceptionally high and relatively stable, suggesting a strong business model.
*   **Equity:** Equity is increasing, indicating a healthy balance sheet.
*   **ROE:** Return on Equity is volatile but shows a positive trend with a large increase in the most recent quarter.

**7. Overall Analysis**

Transmedics Group Inc (TMDX) exhibits strong growth characteristics, as evidenced by its high revenue growth rate, profit margins, and expected future returns. The company has significantly outperformed the S&P 500, driven by recent earnings surprises and positive market sentiment. However, the stock is currently overbought and has high volatility. Investors should be aware of the potential for a correction and consider the elevated MDD figures.

**Key Takeaways:**

*   **Growth Stock:** TMDX shows compelling growth potential.
*   **High Risk/High Reward:** The high MDD and beta indicate significant risk.
*   **Overbought:** The RSI suggests a potential pullback.
*   **Monitor News:** Recent news and events are impacting the stock.
*   **Strong Financials:** Solid revenue growth, high profit margins, and increasing equity are positive signs.

**Recommendation:**

While TMDX presents a compelling investment opportunity due to its growth and strong financials, the overbought conditions and high volatility warrant caution. Investors should conduct further due diligence, monitor news flow, and consider a phased entry to mitigate risk.

